Pfizer (NYSE: PFE) and Warner Chilcott (NASDAQ:WCRX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
This is a summary of recent ratings and recommmendations for Pfizer and Warner Chilcott, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings and Valuation
This table compares Pfizer and Warner Chilcott’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pfizer||$52.55 billion||4.11||$21.31 billion||$3.52||10.30|
Pfizer has higher revenue and earnings than Warner Chilcott.
This table compares Pfizer and Warner Chilcott’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Pfizer pays an annual dividend of $1.36 per share and has a dividend yield of 3.8%. Warner Chilcott does not pay a dividend. Pfizer pays out 38.6% of its earnings in the form of a dividend. Warner Chilcott has increased its dividend for 8 consecutive years.
Institutional and Insider Ownership
70.1% of Pfizer shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Pfizer beats Warner Chilcott on 8 of the 10 factors compared between the two stocks.
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
About Warner Chilcott
Warner Chilcott Public Limited Company is a specialty pharmaceutical company. The Company is focused on the women’s healthcare, gastroenterology, dermatology and urology segments of the branded pharmaceuticals market, primarily in North America. The Company’s hormonal contraceptive product offerings include LOESTRIN 24 FE (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), the branded product in the United States hormonal contraception market, and LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), its new oral contraceptive product, launched in January 2011, that offers women the lowest dosage of estrogen of any oral contraceptive available in the United States market. In October 2013, Actavis Inc acquired the entire share capital of Warner Chilcott PLC.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.